Co-Authors
This is a "connection" page, showing publications co-authored by Hendrik Schulze-Koops and Klaus Krueger.
Connection Strength
2.885
-
Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So et al. Ann Rheum Dis. 2020 Jun 24.
Score: 0.889
-
Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Ann Rheum Dis. 2020 06; 79(6):840-842.
Score: 0.879
-
Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'. Ann Rheum Dis. 2020 Oct 30.
Score: 0.228
-
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al. Ann Rheum Dis. 2020 Aug 04.
Score: 0.224
-
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. 2021 05; 80(5):e67.
Score: 0.222
-
Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al. Ann Rheum Dis. 2020 Jun 23.
Score: 0.222
-
No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al. Ann Rheum Dis. 2020 May 31.
Score: 0.221